1186607-69-1

Basic information

• Product Name: 2,6-difluoro-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(phenylsulfonamido)benzamide
• Synonyms: 2,6-difluoro-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(phenylsulfonamido)benzamide
• CAS NO: 1186607-69-1
• Molecular Weight: 459.433
• Mol File: 1186607-69-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2,6-difluoro-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(phenylsulfonamido)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-difluoro-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(phenylsulfonamido)benzamide(1186607-69-1)
• EPA Substance Registry System: 2,6-difluoro-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(phenylsulfonamido)benzamide(1186607-69-1)

Safety Data

• Hazardous Substances Data: 1186607-69-1(Hazardous Substances Data)

Upstream product

• 84832-02-0 methyl 3-amino-2,6-difluorobenzoate 
• 1269421-43-3 methyl 2,6-difluoro-3-(N-(phenylsulfonyl)(phenylsulfonamido))benzoate 
• 1186609-65-3 3-methoxy-1H-pyrazolo[3,4-b]pyridine-5-amine 
• 1269421-44-4 2,6-difluoro-3-(phenylsulfonamido)benzoic acid 
• 98-09-9 benzenesulfonyl chloride 
• 83141-10-0 2,6-difluoro-3-nitrobenzoic acid 
• 1186609-50-6 2,6-difluoro-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-nitrobenzamide 
• 1186609-51-7 3-amino-2,6-difluoro-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)benzamide 

Relevant articles and documents

Light-controlled inhibition of BRAFV600E kinase

Metastatic melanoma is amongst the most difficult types of cancer to treat, with current therapies mainly relying on the inhibition of the BRAFV600E mutant kinase. However, systemic inhibition of BRAF by small molecule drugs in cancer patients results – paradoxically – in increased wild-type BRAF activity in healthy tissue, causing side-effects and even the formation of new tumors. Here we show the development of BRAFV600E kinase inhibitors of which the activity can be switched on and off reversibly with light, offering the possibility to overcome problems of systemic drug activity by selectively activating the drug at the desired site of action. Based on a known inhibitor, eight photoswitchable effectors containing an azobenzene photoswitch were designed, synthesized and evaluated. The most promising inhibitor showed an approximately 10-fold increase in activity upon light-activation. This research offers inspiration for the development of therapies for metastatic melanoma in which tumor tissue is treated with an active BRAFV600E inhibitor with high spatial and temporal resolution, thus limiting the damage to other tissues.